Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

mrd4 Jul. 5 at 1:32 PM

$BMEA from tipranks: This update could positively impact Biomea Fusion Inc.’s stock performance by boosting investor confidence in the company’s innovative approach to T1D treatment. The competitive landscape in diabetes treatment is evolving, and successful outcomes could position Biomea as a leader in this space.

1 · Reply

mrd4 Jul. 5 at 9:39 AM

$BMEA from chatgpt: A relief rally in Biomea Fusion Inc. (BMEA) may be imminent following the latest clinical update. While the news lacks new efficacy data, it confirms continued progress in the BMF-219 study, easing fears of delays or trial suspension. After significant share price decline, the market is primed to react positively to any sign of stability. The absence of negative developments, combined with renewed investor attention, could trigger short-term upside as sentiment improves and speculative interest returns.

0 · Reply

JuditJager Jul. 4 at 5:35 PM

$BMEA Biomea Fusion’s Phase 2 Trial: A New Hope for Type 1 Diabetes Treatment | https://tipranks.onelink.me/WJho/0vqv5mpy

2 · Reply

Edgehockey Jul. 4 at 10:00 AM

$BMEA I'm long BMEA and want to clear up some notions on the CVI passive investment. First, this is a tiny commitment by this huge institution. It hardly registers on their holdings. They are not here to save longs....they are merely taking a flyer in this name. "They are accountable to their shareholders." What does that even mean? CVI is a money manager who has LPs that invest with them. This $12 million dollar investment gets lost in their sofa cushions. "They are well known investors in biotech." Really? Prove it. Man there are a lot of rookies investing in this name. I want to own more as the shorts work this down.

0 · Reply

Patoun Jul. 3 at 5:56 PM

$BMEA A viable driver is given by the fact CVI bought 5.7 millions shares at $2 a few days ago. They know what they are doing. They are well known investors in biotechs. They are accountable to their shareholders. Biomea is a 2 years target stock. It can easily reach 30 or 40. Remember... biomea already went from $18 in 2021 to $2.x in may 2022 and then jumped to $43.69 on june 2024 8th ...

1 · Reply

Patoun Jul. 3 at 5:23 PM

$BMEA Buy regularly, and forget it. The current low price may be such an opportunity for the long term. They sell, we buy.

1 · Reply

Patoun Jul. 3 at 5:20 PM

$BMEA Cvi acquired 9.9% of biomea a few days ago, see 13G filling. That's around 5.7 M shares.... Those here still trying to spread fear and stress should think twice. I tend to trust more professionnal investors than retail traders desperately trying to make a few bucks benefits CVI, as managed by Heights Capital Management, is an investment firm that has made a substantial bet on Biomea Fusion. This indicates their belief in the company's future and provides Biomea with valuable capital Heights Capital Management is known for its focus on life sciences and technology companies, often engaging in structured finance and PIPE (Private Investment in Public Equity) deals. The purchase of a 9.9% stake is significant : it is a substantial position for an institutional investor. It signals a notable level of confidence in Biomea Fusion's potential, particularly its drug pipeline and future prospects. This can be interpreted by other investors as a positive endorsement.

0 · Reply

Patoun Jul. 3 at 5:16 PM

$BMEA Biomea's BMF positive data last june 13th is a real game changer for the company, at all scales. Why? Simply, because it is going to ease a strategic alliance with a top pharma company and will bring fresh cash without dillution. This will even be rellutive as bringing tremendous value to Biomea. The diabete program will then be secured while in parallel also having the oncology program on its rails... Not sure there are many companies with such a huge potential on the market (x 30 x40) for the next few years, not even AI firms..

2 · Reply

nf04 Jul. 3 at 5:05 PM

$BMEA interesting movement at the end and volume picking up! might be just shorts covering for the long weekend but you know there were whales grabbing some low price liquidity kindly provided by the short sellers; more recovery ahead for next week, probably some resistance around 2.00 as reasoned earlier.

0 · Reply

Heids24 Jul. 3 at 5:02 PM

$BMEA Nice finish with some volume. Signs of a short term turn around???

0 · Reply

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 18 days ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 18 days ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 11:15 PM EDT - 19 days ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025, 7:28 PM EDT - 19 days ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

Jun 17, 2025, 4:33 PM EDT - 19 days ago

Biomea Fusion Announces Proposed Public Offering of Securities

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 23 days ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 7 weeks ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 2 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 4:01 PM EDT - 3 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 3 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 25, 2025, 7:00 PM EDT - 3 months ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 3 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 3, 2025, 8:00 AM EST - 4 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2025, 8:00 AM EST - 4 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Dec 17, 2024, 10:41 AM EST - 7 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 8:10 AM EST - 7 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 16, 2024, 6:15 PM EST - 7 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 7 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 7 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 7 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Nov 3, 2024, 11:00 AM EST - 8 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 8 months ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 30, 2024, 4:00 PM EDT - 8 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 29, 2024, 4:46 PM EDT - 8 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 11:00 AM EDT - 8 months ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 28, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 26, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 21, 2024, 9:00 AM EDT - 9 months ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 20, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions$

Oct 19, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 18, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions$

Oct 17, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 15, 2024, 4:05 PM EDT - 9 months ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 8, 2024, 11:00 AM EDT - 9 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Oct 7, 2024, 9:00 AM EDT - 9 months ago

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

mrd4 Jul. 5 at 1:32 PM

1 · Reply

mrd4 Jul. 5 at 9:39 AM

0 · Reply

JuditJager Jul. 4 at 5:35 PM

$BMEA Biomea Fusion’s Phase 2 Trial: A New Hope for Type 1 Diabetes Treatment | https://tipranks.onelink.me/WJho/0vqv5mpy

2 · Reply

Edgehockey Jul. 4 at 10:00 AM

0 · Reply

Patoun Jul. 3 at 5:56 PM

1 · Reply

Patoun Jul. 3 at 5:23 PM

$BMEA Buy regularly, and forget it. The current low price may be such an opportunity for the long term. They sell, we buy.

1 · Reply

Patoun Jul. 3 at 5:20 PM

0 · Reply

Patoun Jul. 3 at 5:16 PM

2 · Reply

nf04 Jul. 3 at 5:05 PM

0 · Reply

Heids24 Jul. 3 at 5:02 PM

$BMEA Nice finish with some volume. Signs of a short term turn around???

0 · Reply

nf04 Jul. 3 at 4:33 PM

$BMEA the company might not dislike that the price is kept below $2 until the underwriter option to purchase another 15% shares of the public offering (3.0M) expires on July 20. The good news is, this expiration is only 10 sessions away. I would expect the Icovamenib 52-week data to come out soon after, too. The current sell trend clearly is close to being exhausted, it will bottom out soon and a couple days of flat will be followed by further upside, just like the price action before June 3.

0 · Reply

JuditJager Jul. 3 at 4:31 PM

$BMEA I really don't understand what's going on here?! All her data are tempting, yet many sell it with loss? I don't hope the $40, but to be in historical minus?! WHY???

1 · Reply

Edgehockey Jul. 3 at 4:02 PM

$BMEA Inability of the small retail buyers to bring any size BUY orders to the market is playing right into the shorts hands! As I predicted. Drip drip drip torture until you throw the towel in. Mgmt doesn't really care. Protecting the stock is not their job; moving the science forward is. I want to own more. Does this go to $1.20? Likely. I will be there.

0 · Reply

hashbridges Jul. 3 at 3:59 PM

$BMEA bought more.

0 · Reply

hashbridges Jul. 3 at 3:56 PM

$BMEA Its trading at $64M market cap as of this moment which is nearly their cash on hand. Totally bizarre. Meant to make us think the results are going to be terrible or something - though I think I'd look for a higher volume dump event of the "front running" thesis to hold out. The volume of buying on June 3rd utterly dwarfs all of the selling. Some buyer stepping in will cause that entire Short Shell Game to collapse quickly like it did back on 6/3-6/17.

0 · Reply

mrd4 Jul. 3 at 3:08 PM

$BMEA It’s not the results that are bad, but the company lacked cash and was therefore sold down from 12 dollars. It’s crazy how much it has dropped. But, that also means it can quickly rise again.

0 · Reply

aquira Jul. 3 at 3:03 PM

$BMEA yhuuuge disappointment

0 · Reply

Kid_Shelleen Jul. 3 at 2:09 PM

$BMEA Bought another 500 shares. Hope they don't dilute us again.

0 · Reply

mrd4 Jul. 3 at 2:02 PM

$BMEA Bought a bunch of shares. this is just qrazy

0 · Reply

ClarkeDevlin Jul. 2 at 11:10 PM

$BMEA when do expect the next data release?

2 · Reply

GODOFUSD Jul. 2 at 9:48 PM

$BMEA Interesting to see this pattern that tend to repeat since the last impulse at the top. Also interesting that CVI investments bought recently +5.8M shares in this zone. Is this the moment to fear or to take a risk ?

0 · Reply

Rob88ynn Jul. 2 at 7:51 PM

$BMEA getting punished

0 · Reply

Market Cap	62.37M
Revenue (ttm)	0.00
Net Income (ttm)	-138.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,289,400
Avg Vol	2,729,304
Day's Range	N/A - N/A
Shares Out	37.57M
Stochastic %K	20%
Beta	-0.13
Analysts	Strong Sell
Price Target	$18.25